Fineline Cube

Follow:
14455 Articles
iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson's Disease Therapy with FDA Fast Track and RMAT Designations
CompanyDeals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

CompanyDrug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

CompanyDrug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

CompanyDrug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
CompanyDeals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
CompanyDrug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

CompanyDrug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

CompanyDeals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

CompanyDrug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors